<DOC>
	<DOCNO>NCT01239043</DOCNO>
	<brief_summary>The purpose trial describe antibody persistence response re-vaccination either Menactra® Menomune® vaccine approximately three year follow initial vaccination adult participate trial MTA29 ( NCT00874549 ) . Objectives : - To describe rate immediate reaction , solicit injection-site systemic reaction , unsolicited adverse event , serious adverse event follow vaccination . - To evaluate persistence serum bactericidal antibodies subject receive Menactra® Menomune® vaccine approximately three year ago . - To evaluate immune response serogroups A , C , Y , W-135 subject re-vaccinated either Menactra® Menomune® vaccine .</brief_summary>
	<brief_title>Antibody Persistence Response Re-vaccination With Either Menactra® Menomune® 3 Years After Initial Vaccination</brief_title>
	<detailed_description>Participants randomize receive either Menactra® Menomune® vaccine trial MTA29 receive 1 dose either Menactra® Menomune® , respectively Day 0 followed-up 28 day post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Aged 56 year old day inclusion . Received appropriate Menactra Menomune vaccine assign randomization Trial MTA29 . Ambulatory healthy , determined medical history . Informed consent form sign date . Able attend schedule visit comply trial procedure . For woman childbearing potential , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination . Any condition , opinion Investigator , would pose health risk participant interfere evaluation vaccine . Known pregnancy , positive pregnancy test . Currently breastfeed child . History document invasive meningococcal disease . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Receipt meningococcal vaccine since participation trial MTA29 . Receipt vaccine 4 week precede trial vaccination , except influenza vaccination , may receive least two week trial vaccination . Planned receipt vaccine 4 week follow trial vaccination . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Laboratoryconfirmed seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C. Previous personal history GuillainBarré Syndrome ( GBS ) . Known systemic hypersensitivity vaccine component , latex , history lifethreatening reaction vaccine use trial vaccine contain substance . Laboratoryconfirmed thrombocytopenia , contraindicate intramuscular ( IM ) vaccination . Bleeding disorder receipt anticoagulants 3 week precede inclusion , contraindicate IM vaccination . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol drug use , opinion Investigator , might interfere ability comply trial procedure . Not available entire study period unable attend schedule visit comply study procedure . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
	<keyword>Meningococcal vaccine</keyword>
</DOC>